Jennifer Griffo, APRN
Gerontology · Reno, NVNPI 1053931386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,268 of the $8,305 with a category attached, or 75.5%. 19 manufacturers reported payments, led by Abbott at 46.4% of the total. Reporting peaked in 2023 at $4,051 and has fallen 71.0% since, to $1,176 in 2025. Among gerontology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $68.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Merck$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Alnylam Pharmaceuticals Inc.$513
- Actelion Pharmaceuticals US, Inc.$232
- Bridgebio Pharma, Inc.$138
- plus $901 from 13 others
What the payments were for
- Travel & lodging$2,03725%
- Food & beverage$6,26875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 44 | $3,853 |
| Merck | 12 | $1,652 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $1,017 |
| Alnylam Pharmaceuticals Inc. | 12 | $513 |
| Actelion Pharmaceuticals US, Inc. | 3 | $232 |
| Bridgebio Pharma, Inc. | 1 | $138 |
| AstraZeneca | 1 | $125 |
| Bayer | 5 | $116 |
| Johnson & Johnson | 6 | $99 |
| Pfizer | 3 | $94 |
| Cvrx, Inc. | 2 | $90 |
| Boston Scientific | 3 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $80 |
| Boehringer Ingelheim | 3 | $63 |
| Novartis | 3 | $56 |
| Novo Nordisk | 2 | $45 |
| Endotronix, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,305 in reported general payments places this provider in the 95th percentile of 72 gerontology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $206,123 |
| JardianceEmpagliflozin | 100 | $134,799 |
| EntrestoSacubitril/Valsartan | 62 | $86,621 |
| FarxigaDapagliflozin Propanediol | 51 | $53,370 |
| XareltoRivaroxaban | 18 | $24,987 |
| Repatha SureclickEvolocumab | 20 | $16,549 |
| Metoprolol Succinate | 312 | $6,492 |
| Rosuvastatin Calcium | 149 | $3,513 |
| Spironolactone | 259 | $3,320 |
| Atorvastatin Calcium | 218 | $3,213 |
| Losartan Potassium | 229 | $2,854 |
| Amiodarone Hcl | 72 | $2,639 |
| Torsemide | 85 | $1,864 |
| ClopidogrelClopidogrel Bisulfate | 83 | $1,828 |
| Ezetimibe | 37 | $1,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $206,123168 claims |
| Boehringer IngelheimJardiance | $63 | $134,799100 claims |
| NovartisEntresto | $56 | $86,62162 claims |
| AstraZenecaFarxiga | $125 | $53,37051 claims |
| Johnson & JohnsonXarelto | $99 | $24,98718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 72 gerontology providers in Nevada.
Other gerontology in Reno
- Elizabeth HasslerReno$7K
- Preston PetersonReno$3K
- Marian GnandtReno$594
- Holly PorterReno$472
- Ann EganReno$453
- Rachel ChattinReno$382
- Marina VyshutinaReno$360
- Caleb FrinkReno$158
- Jennifer LanghamReno$148
- Deborah WalkerReno$122
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.